Inflammatory Myopathies: Update on Diagnosis, Pathogenesis and Therapies, and COVID-19-related Implications

Overview

Journal Acta Myol

Date 2021 Jan 18

PMID 33458584

Citations 29

Authors

Marinos C Dalakas

Affiliations

Soon will be listed here.

Abstract

The inflammatory myopathies constitute a heterogeneous group of acquired myopathies that have in common the presence of endomysial inflammation. Based on steadily evolved clinical, histological and immunopathological features and some autoantibody associations, these disorders can now be classified in five characteristic subsets: Dermatomyositis (DM) Polymyositis (PM), Necrotizing Autoimmune Myositis (NAM), Anti-synthetase syndrome-overlap myositis (Anti-SS-OM), and Inclusion-Body-Myositis (IBM). Each inflammatory myopathy subset has distinct immunopathogenesis, prognosis and response to immunotherapies, necessitating the need to correctly identify each subtype from the outset to avoid disease mimics and proceed to early therapy initiation. The review presents the main clinicopathologic characteristics of each subset highlighting the importance of combining expertise in clinical neurological examination with muscle morphology and immunopathology to avoid erroneous diagnoses and therapeutic schemes. The main autoimmune markers related to autoreactive T cells, B cells, autoantibodies and cytokines are presented and the concomitant myodegenerative features seen in IBM muscles are pointed out. Most importantly, unsettled issues related to a role of autoantibodies and controversies with reference to possible triggering factors related to statins are clarified. The emerging effect SARS-CoV-2 as the cause of hyperCKemia and potentially NAM is addressed and practical guidelines on the best therapeutic approaches and concerns regarding immunotherapies during COVID-19 pandemic are summarized.

Citing Articles

IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma.

Guo Y, Shen B, Lou C, Wang L, Li Y Discov Oncol. 2024; 15(1):599.

PMID: 39470901 PMC: 11522225. DOI: 10.1007/s12672-024-01483-2.

Heterogeneity in nomenclature and abbreviation usage for anti-synthetase syndrome: a scoping review.

Aggarwal A, Chandra T, Ladha P, Mittal S, Haldule S, Nirmal S Rheumatol Int. 2024; 44(11):2293-2299.

PMID: 39212691 DOI: 10.1007/s00296-024-05670-w.

Severe Post-Viral Polymyositis after COVID-19 in Childhood: A Case Report and Literature Review.

Marciulynaite J, Sileikiene R, Snipaitiene A Children (Basel). 2024; 11(8).

PMID: 39201945 PMC: 11352915. DOI: 10.3390/children11081011.

Inflammatory Myositis Following Statin Use in a Patient With Untreated Hypothyroidism.

Renteria M, Jilani M, Brockman M, Davis H Cureus. 2023; 15(11):e48463.

PMID: 38073998 PMC: 10703509. DOI: 10.7759/cureus.48463.

Inclusion body myositis-health-related quality of life and care situation during phases of the "patience journey" in Germany: results from a qualitative study.

Senn K, Thiele S, Gumbert L, Krause S, Walter M, Nagels K Health Qual Life Outcomes. 2023; 21(1):111.

PMID: 37817114 PMC: 10566017. DOI: 10.1186/s12955-023-02196-w.

References

Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T . Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011; 50(7):1344-6. DOI: 10.1093/rheumatology/ker152. View

De Bleecker J, De Paepe B, Vanwalleghem I, Schroder J . Differential expression of chemokines in inflammatory myopathies. Neurology. 2002; 58(12):1779-85. DOI: 10.1212/wnl.58.12.1779. View

Dalakas M . Images in clinical medicine. Calcifications in dermatomyositis. N Engl J Med. 1995; 333(15):978. DOI: 10.1056/NEJM199510123331506. View

Dalakas M . Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006; 2(8):437-47. DOI: 10.1038/ncpneuro0261. View

Askanas V, Engel W, Nogalska A . Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta. 2014; 1852(4):633-43. DOI: 10.1016/j.bbadis.2014.09.005. View

Alshehri A, Choksi R, Bucelli R, Pestronk A . Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm. 2015; 2(4):e124. PMC: 4459046. DOI: 10.1212/NXI.0000000000000124. View

Badrising U, van Duinen S, Breedveld F, van Doorn P, Van Engelen B, van den Hoogen F . Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000; 55(9):1385-7. DOI: 10.1212/wnl.55.9.1385. View

Dalakas M . Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011; 40(4 Pt 2):e237-47. DOI: 10.1016/j.lpm.2011.01.005. View

Bradshaw E, Orihuela A, McArdel S, Salajegheh M, Amato A, Hafler D . A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol. 2006; 178(1):547-56. DOI: 10.4049/jimmunol.178.1.547. View

10.

Pluk H, van Hoeve B, van Dooren S, Stammen-Vogelzangs J, van der Heijden A, Schelhaas H . Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013; 73(3):397-407. DOI: 10.1002/ana.23822. View

11.

Plotz P, Dalakas M, Leff R, Love L, Miller F, Cronin M . Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med. 1989; 111(2):143-57. DOI: 10.7326/0003-4819-111-2-143. View

12.

Dalakas M, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K . Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997; 48(3):712-6. DOI: 10.1212/wnl.48.3.712. View

13.

Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas M . Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain. 2008; 131(Pt 5):1228-40. PMC: 2367696. DOI: 10.1093/brain/awn053. View

14.

Schmidt J, Barthel K, Zschuntzsch J, Muth I, Swindle E, Hombach A . Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death. Brain. 2012; 135(Pt 4):1102-14. DOI: 10.1093/brain/aws046. View

15.

Cupler E, Miller J, Semino-Mora C, Anderson T, Dalakas M . Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain. 1996; 119 ( Pt 6):1887-93. DOI: 10.1093/brain/119.6.1887. View

16.

Engel A, Arahata K . Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986; 17(7):704-21. DOI: 10.1016/s0046-8177(86)80180-0. View

17.

Ernste F, Reed A . Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013; 88(1):83-105. DOI: 10.1016/j.mayocp.2012.10.017. View

18.

Dastmalchi M, Grundtman C, Alexanderson H, Mavragani C, Einarsdottir H, Helmers S . A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008; 67(12):1670-7. DOI: 10.1136/ard.2007.077974. View

19.

Needham M, Mastaglia F . Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007; 6(7):620-31. DOI: 10.1016/S1474-4422(07)70171-0. View

20.

OHanlon T, Dalakas M, Plotz P, Miller F . Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol. 1994; 152(5):2569-76. View